Suspension of trading
Valuation SpringWorks Therapeutics, Inc.
Stocks
SWTX
US85205L1070
Pharmaceuticals
|
Market Closed -
Nasdaq
21:00:00 30/06/2025 BST
|
5-day change | 1st Jan Change | ||
| 46.99 USD | +0.02% |
|
-.--% | - |
| 12-15 | Immunome jumps after promising results for its desmoid tumor treatment |  |
| 12-01 | Tyra Bioscience Appoints Bhavesh Ashar as Chief Operating Officer | MT |
Company Valuation: SpringWorks Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 1,655 | 3,476 | 3,020 | 1,616 | 2,630 | 2,687 |
| Change | - | 109.99% | -13.11% | -46.49% | 62.74% | 2.16% |
| Enterprise Value (EV) 1 | 1,328 | 2,917 | 2,589 | 1,024 | 1,975 | 2,233 |
| Change | - | 119.7% | -11.25% | -60.43% | 92.75% | 13.08% |
| P/E | -10.1x | -68.9x | -17.3x | -5x | -7.09x | -10.4x |
| PBR | 5.14x | 6.27x | 7.16x | 2.9x | 4.28x | 5.59x |
| PEG | - | 1x | -0x | -0.1x | 6.65x | 0.3x |
| Capitalization / Revenue | - | 99,312,098x | - | - | 482,854,888x | 14,023,842x |
| EV / Revenue | - | - | - | - | - | - |
| EV / EBITDA | -22.5x | -63.4x | -15x | -3.66x | -5.78x | -8.13x |
| EV / EBIT | -22.4x | -63x | -14.9x | -3.65x | -5.76x | -8.03x |
| EV / FCF | -46.7x | -181x | -40.8x | -11.6x | -17.4x | -20x |
| FCF Yield | -2.14% | -0.55% | -2.45% | -8.62% | -5.73% | -5% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | -3.81 | -1.053 | -3.586 | -5.206 | -5.15 | -3.482 |
| Distribution rate | - | - | - | - | - | - |
| Net sales | - | 35 | - | - | 5.447 | 191.6 |
| EBITDA 1 | -59.05 | -45.98 | -173 | -279.9 | -341.3 | -274.7 |
| EBIT 1 | -59.24 | -46.32 | -173.5 | -280.7 | -343 | -278.1 |
| Net income 1 | -58.31 | -45.57 | -173.9 | -277.4 | -325.1 | -258.1 |
| Net Debt 1 | -327.7 | -559.1 | -431.4 | -591.8 | -655.5 | -454 |
| Reference price 2 | 38.49 | 72.52 | 61.98 | 26.01 | 36.50 | 36.13 |
| Nbr of stocks (in thousands) | 43,006 | 47,931 | 48,727 | 62,137 | 72,058 | 74,365 |
| Announcement Date | 12/03/20 | 25/02/21 | 24/02/22 | 28/02/23 | 27/02/24 | 20/02/25 |
1USD in Million2USD
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 3.54B | |
| 18.76x | 4.38x | 10.31x | 0.48% | 80.91B | |
| 37.28x | 12.74x | 24.23x | -.--% | 50.13B | |
| 21.76x | 4.81x | 13.74x | 0.67% | 47.97B | |
| 18.53x | 4x | 12.31x | 2.68% | 53.62B | |
| 37.77x | 3.48x | 13.26x | -.--% | 31.41B | |
| -7.34x | 10.2x | -6.58x | -.--% | 25.14B | |
| 54.39x | 3.5x | 27.09x | -.--% | 25.03B | |
| 71.69x | 6.93x | 46.4x | -.--% | 21.45B | |
| 24.35x | 5.22x | 13.6x | -.--% | 16.93B | |
| Average | 30.80x | 6.14x | 17.15x | 0.43% | 35.61B | |
| Weighted average by Cap. | 27.62x | 6.03x | 15.66x | 0.61% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- SWTX Stock
- Valuation SpringWorks Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
